Discover
Stelara (ustekinumab) / J&JREAL WORLD EXPERIENCE WITH USTEKINUMAB IN PAEDIATRIC CROHN´S DISEASE. A MULTICENTRE RETROSPECTIVE STUDY FROM PAEDIATRIC IBD PORTO GROUP OF ESPGHAN (UEGW 2019) - Oct 4, 2019 - Abstract #LB05; Pres time: Oct 21, 2019; 02:48 PM - 03:00 PM; Location: F3; "This abstract will be published on October 21, 2019"Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi launch estimate: 2022 for Crohn’s disease and 2023 for ulcerative colitis (UBS) - Oct 2, 2019 - A subscription to Thomson ONE is required to gain full access to report 68017232; Page no: 1; REPORT TITLE: "US Pharmaceuticals "Gastroenterology – Takeaways from UBS expert symposium"”; AUTHOR: Jacob, Navin, et al; DATE: 09/26/2019Humira (adalimumab) / Eisai, AbbVieAn open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with ulcerative cOlitis initiating adalimumab : The CONTROL trial (clinicaltrialsregister.eu) - Oct 5, 2019 - P4; N=238; Ongoing; Sponsor: GETAIDInflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer; Remsima SC (infliximab biosimilar SC) / CelltrionNONINFERIORITY OF NOVEL SUBCUTANEOUS INFLIXIMAB (CT-P13) TO INTRAVENOUS INFLIXIMAB (CT-P13) IN PATIENTS WITH ACTIVE CROHN’S DISEASE AND ULCERATIVE COLITIS: WEEK 30 RESULTS FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL (UEGW 2019) - Oct 4, 2019 - Abstract #LB02; Pres time: Oct 21, 2019; 02:12 PM - 02:24 PM; Location: F3; "This abstract will be published on October 21, 2019"Entyvio (vedolizumab) / TakedaEntyvio sales projection: $4.3B by 2022 (Deutsche Bank Research) - Oct 1, 2019 - A subscription to Thomson ONE is required to gain full access to report 67968779; Page no: 2; REPORT TITLE: "Roche: Pharma day; biosimilar headwinds should soon be in the rear view”; AUTHOR: Parkes, Richard, et al; DATE: 09/17/2019Rinvoq (upadacitinib) / AbbVieRinvoq sales projection: $5.6B peak (UBS) - Oct 5, 2019 - A subscription to Thomson ONE is required to gain full access to report 68016563; Page no: 1; REPORT TITLE: "US Pharmaceuticals "UBS healthcare expert symposium: Dermatology panel key ...”; AUTHOR: Jacob, Navin, et al; DATE: 09/26/2019etrolizumab (RG7413) / RocheEtrolizumab sales projection: CHF765M in 2025 (Deutsche Bank Research) - Oct 4, 2019 - A subscription to Thomson ONE is required to gain full access to report 67968779; Page no: 2; REPORT TITLE: "Roche Holding Ltd- Roche: Pharma Day; Biosimilar headwinds should soon be in the rear view"; AUTHOR: Parkes, Richard, et al; DATE: 09/17/2019Sales projectionOtezla (apremilast) / AmgenOtezla sales projection: $1.9B in 2019 and $2.2B in 2020 (Cowen & Co) - Sep 30, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2914; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019BMS-986165 / BMSBMS-986165 sales projection: Consensus of $3.5B peak (Exane BNP Paribas) - Oct 4, 2019 - A subscription to Thomson ONE is required to gain full access to report 67972680; Page no: 38; REPORT TITLE: "Pharmaceuticals: Champions League 2019: Powered by pulse "; AUTHOR: Hector, Luisa, et al; DATE: 09/17/2019Xeljanz (tofacitinib) / PfizerXeljanz sales projection: $1B peak for gastrointestinal disorders (UBS) - Oct 2, 2019 - A subscription to Thomson ONE is required to gain full access to report 68017232; Page no: 1; REPORT TITLE: "US Pharmaceuticals "Gastroenterology – Takeaways from UBS expert symposium"”; AUTHOR: Jacob, Navin, et al; DATE: 09/26/2019
